October 1, 2018 10:41 AM EDT
News Briefing

Mo­men­ta whacks top ex­ecs, 110 jobs in re­struc­tur­ing; Genen­tech gains $62M in R&D back­ing from BAR­DA

John Carroll

Editor & Founder

→ Mo­men­ta Phar­ma­ceu­ti­cals $MN­TA is re­struc­tur­ing, boot­ing 110 jobs and a slate of ex­ecs in search of some deep bud­get cuts. As part of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times